Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study

被引：0
|
作者：
Miles, D.
Baselga, J.
Amadori, D.
Sunpaweravong, P.
Semiglazov, V.
Knott, A.
Clark, E.
Ross, G.
Swain, S. M.
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[5] Prince Songkla Univ, Songklanagarind Hosp, Hat Yai, Thailand
[6] NN Petrov Res Inst Oncol, St Petersburg, Russia
[7] Roche Prod Ltd, Welwyn Garden City, England
[8] MedStar Washington Hosp Ctr, Washington, DC USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P5-18-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-18-01
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
    Luai S. Al Rabadi
    Madeline M. Cook
    Andy J. Kaempf
    Megan M. Saraceni
    Michael A. Savin
    Zahi I. Mitri
    BMC Cancer, 21
  • [42] Pertuzumab biosimilar in HER2-positive metastatic breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (01) : 21 - 21
  • [43] Complete response after pertuzumab plus trastuzumab plus docetaxel in metastatic Her2-positive breast cancer patients: review of four cases
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 845 - 846
  • [44] Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
    Swain, Sandra M.
    Ewer, Michael S.
    Cortes, Javier
    Amadori, Dino
    Miles, David
    Knott, Adam
    Clark, Emma
    Benyunes, Mark C.
    Ross, Graham
    Baselga, Jose
    ONCOLOGIST, 2013, 18 (03): : 257 - 264
  • [45] Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
    You, Shuhui
    Xie, Yizhao
    Sang, Die
    Luo, Ting
    Yuan, Peng
    Xu, Fei
    Wang, Biyun
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [46] Pertuzumab plus trastuzumab increases survival in patients with HER2-positive breast cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (11) : 611 - 611
  • [47] Trastuzumab emtansine in HER2-positive metastatic breast cancer after pertuzumab and trastuzumab: TDM1RM Study
    Martinez-Garcia, J.
    Puertes Boix, A.
    Sanchez Henarejos, P.
    Jimenez Lucas, M. D.
    Sanchez Saura, A.
    Luengo, M.
    Carrillo Vicente, R.
    Martinez Ortiz, M. J.
    Balsalobre, J.
    de la Morena Barrio, P. D. L. M.
    Garcia Garre, E.
    Garcia, E.
    Marin, G.
    Garcia Torralba, E.
    Ayala de la Pena, F.
    Collado, D.
    Lopez, A.
    Quiros, T.
    Sanchez, D. A.
    Romero, J. L. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S358 - S358
  • [48] An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
    Cardoso, Fatima
    Canon, Jean-Luc
    Amadori, Dino
    Aldrighetti, Daniela
    Machiels, Jean-Pascal
    Bouko, Yasmina
    Verkh, Lev
    Usari, Tiziana
    Kern, Kenneth A.
    Giorgetti, Carla
    Dirix, Luc
    BREAST, 2012, 21 (06): : 716 - 723
  • [49] Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study
    Orlando, Laura
    Giotta, Francesco
    Lorusso, Vito
    De Vita, Ferdinando
    Filippelli, Gianfranco
    Maiello, Evaristo
    Riccardi, Ferdinando
    Pappagallo, Giovanni Luigi
    Fedele, Palma
    Gebbia, Nicola
    Verderame, Francesco
    Barni, Sandro
    Blasi, Livio
    Pisconti, Salvatore
    Colucci, Giuseppe
    Cinieri, Saverio
    FUTURE ONCOLOGY, 2014, 10 (05) : 725 - 733
  • [50] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study
    F Carabantes-Ocón
    E Saez-Lara
    L Burgos-Garcia
    E Villar-Chamorro
    A Casaus-Hazañas
    S Luna
    C Martínez
    Breast Cancer Research, 9
12345